These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30826934)

  • 61. Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti-triple-negative breast cancer efficacy in vitro and in vivo.
    Ren YL; Lei JT; Zhang TR; Lu P; Cui DD; Yang B; Zhao GY; Peng F; Cao ZX; Peng C; Li YZ
    Phytother Res; 2024 Apr; 38(4):1815-1829. PubMed ID: 38349045
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.
    Anwar MM; Shalaby M; Embaby AM; Saeed H; Agwa MM; Hussein A
    Sci Rep; 2020 Sep; 10(1):14706. PubMed ID: 32895397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
    He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
    Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer.
    Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
    Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intermittent Fasting Attenuates Obesity-Induced Triple-Negative Breast Cancer Progression by Disrupting Cell Cycle, Epithelial-Mesenchymal Transition, Immune Contexture, and Proinflammatory Signature.
    Son DS; Done KA; Son J; Izban MG; Virgous C; Lee ES; Adunyah SE
    Nutrients; 2024 Jul; 16(13):. PubMed ID: 38999849
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer.
    Huang CC; Hsu CM; Chao MW; Hsu KC; Lin TE; Yen SC; Tu HJ; Pan SL
    Protein Sci; 2024 Jun; 33(6):e5004. PubMed ID: 38723164
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exploration of the Pharmacological Mechanism of Vitexicarpin against Triple-Negative Breast Cancer in Network Pharmacology.
    Wu T; Xiang M; Li Y; Gao Y; Teng D; Sun M; Guo W; Zhou Y
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):341. PubMed ID: 38179762
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lysophosphatidic Acid Receptor 1 (LPA
    Liu W; Mousa AAK; Hopkins AM; Wu YF; Thu KL; Campbell M; Lees SJ; Ramachandran R; Hou J
    ChemMedChem; 2024 Aug; 19(16):e202400013. PubMed ID: 38648251
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/β-Catenin Pathway.
    Liu W; Chen G; Sun L; Zhang Y; Han J; Dai Y; He J; Shi S; Chen B
    Front Oncol; 2019; 9():617. PubMed ID: 31338333
    [No Abstract]   [Full Text] [Related]  

  • 70. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
    Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H
    Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer.
    Xie X; Chauhan GB; Edupuganti R; Kogawa T; Park J; Tacam M; Tan AW; Mughees M; Vidhu F; Liu DD; Taliaferro JM; Pitner MK; Browning LS; Lee JH; Shen Y; Wang J; Ueno NT; Krishnamurthy S; Hortobagyi GN; Tripathy D; Van Laere SJ; Bartholomeusz G; Dalby KN; Bartholomeusz C
    Cancer Res Commun; 2023 Jun; 3(6):1078-1092. PubMed ID: 37377604
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice.
    Dong J; Kong L; Wang S; Xia M; Zhang Y; Wu J; Yang F; Zuo S; Wei J
    J Exp Clin Cancer Res; 2024 Apr; 43(1):102. PubMed ID: 38566092
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Resveratrol-derived inhibitors of the E3 ubiquitin ligase PELI1 inhibit the metastasis of triple-negative breast cancer.
    Xu G; Zhou Q; Qi J; Li Z; Yin L; Li Z; Lu C; Zhao B; Shen Y
    Eur J Med Chem; 2024 Feb; 265():116060. PubMed ID: 38150964
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.
    Carney CP; Kapur A; Anastasiadis P; Ritzel RM; Chen C; Woodworth GF; Winkles JA; Kim AJ
    Mol Pharm; 2023 Jan; 20(1):314-330. PubMed ID: 36374573
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Scutellarin suppresses triple-negative breast cancer metastasis by inhibiting TNFα-induced vascular endothelial barrier breakdown.
    Mei XY; Zhang JN; Jia WY; Lu B; Wang MN; Zhang TY; Ji LL
    Acta Pharmacol Sin; 2022 Oct; 43(10):2666-2677. PubMed ID: 35228654
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of ERK signaling for treatment of ERRα positive TNBC.
    Musheyev D; Miller E; Birnbaum N; Miller E; Erblich S; Schuck A; Alayev A
    PLoS One; 2023; 18(5):e0283047. PubMed ID: 37163498
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
    Sofianidi A; Dumbrava EE; Syrigos KN; Nasrazadani A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539474
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of NuMA1 in breast cancer stem cells with implications for combination therapy of PIM1 and autophagy inhibition in triple negative breast cancer.
    Manupati K; Hao M; Haas M; Yeo SK; Guan JL
    Res Sq; 2024 Apr; ():. PubMed ID: 38645153
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of PROTAC degrader probe of CDK4/6 based on DCAF16.
    Pu C; Liu Y; Deng R; Xu Q; Wang S; Zhang H; Luo D; Ma X; Tong Y; Li R
    Bioorg Chem; 2023 Sep; 138():106637. PubMed ID: 37276679
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer.
    Garlapati C; Joshi S; Bhattarai S; Krishnamurthy J; Turaga RC; Nguyen T; Li X; Aneja R
    Cell Death Dis; 2023 Jan; 14(1):12. PubMed ID: 36627281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.